Functional genomics of GPR126 in airway smooth muscle and bronchial epithelial cells by Hall, Robert J. et al.
The FASEB Journal. 2021;35:e21300.    | 1 of 14wileyonlinelibrary.com/journal/fsb2
Received: 11 September 2020 | Revised: 1 December 2020 | Accepted: 7 December 2020
DOI: 10.1096/fj.202002073R  
R E S E A R C H  A R T I C L E
Functional genomics of GPR126 in airway smooth muscle and 
bronchial epithelial cells
Robert J. Hall  |   Jonathan O’Loughlin |   Charlotte K. Billington |   Dhruma Thakker |   
Ian P. Hall |   Ian Sayers
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.
Ian P. Hall and Ian Sayers contributed equally.  
Abbreviations: 7TM, 7 transmembrane spanning region; aGPCR, adhesion G Protein- coupled receptor; COPD, chronic obstructive pulmonary disease; 
CUB, complement C1r/C1s, Uegf, Bmp1; ECD, extracellular domain; ECM, extracellular matrix; eQTL, expression quantitative trait loci; FDR, false 
discovery rate; FEV1, forced expired volume in 1 second; FVC, forced vital capacity; GAIN, GPCR autoproteolysis- inducing; GPCR, G protein- coupled 
receptor; GPS, GPCR proteolysis site; GSEA, gene set enrichment analysis; GWAS, genome wide association study; HASM, human airway smooth muscle; 
HBEC, human bronchial epithelial cell; LD, linkage disequilibrium; PTX, Pentraxin; RNA- seq, RNA- sequencing; SNP, single nucleotide polymorphism.
Division of Respiratory Medicine, National 
Institute for Health Research, Nottingham 
Biomedical Research Centre, Biodiscovery 
Institute, University of Nottingham, 
Nottingham, UK
Correspondence
Robert Hall, Division of Respiratory 
Medicine, National Institute for Health 
Research, Nottingham Biomedical Research 
Centre, Biodiscovery Institute, University of 
Nottingham, Nottingham, NG7 2RD, UK.
Email: robert.hall@nottingham.ac.uk
Funding information
Hermes Fellowship University of 
Nottingham, Grant/Award Number: 2016- 
2017; British Lung Foundation (BLF), 
Grant/Award Number: Grant PPRG15- 5; 
RCUK | Medical Research Council (MRC), 
Grant/Award Number: G1000861; NIHR 
Senior Investigator award; The Centre 
of Membrane Proteins and Receptors 
(COMPARE)
Abstract
GPR126 is an adhesion G protein- coupled receptor which lies on chromosome 6q24. 
Genetic variants in this region are reproducibly associated with lung function and 
COPD in genome wide association studies (GWAS). The aims of this study were to 
define the role of GPR126 in the human lung and in pulmonary disease and identify 
possible casual variants. Online tools (GTEx and LDlink) identified SNPs which may 
have effects on GPR126 function/ expression, including missense variant Ser123Gly 
and an intronic variant that shows eQTL effects on GPR126 expression. GPR126 
signaling via cAMP- mediated pathways was identified in human structural airway 
cells when activated with the tethered agonist, stachel. RNA- seq was used to iden-
tify downstream genes/ pathways affected by stachel- mediated GPR126 activation 
in human airway smooth muscle cells. We identified ~350 differentially expressed 
genes at 4 and 24 hours post stimulation with ~20% overlap. We identified that genes 
regulated by GPR126 activation include IL33, CTGF, and SERPINE1, which al-
ready have known roles in lung biology. Pathways altered by GPR126 included those 
involved in cell cycle progression and cell proliferation. Here, we suggest a role for 
GPR126 in airway remodeling.
K E Y W O R D S
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1 |  INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a major 
worldwide cause of morbidity and mortality.1,2 Treatments 
can alleviate symptoms yet there is an unmet need for 
therapeutic interventions that can halt or reverse disease 
progression. Risk factors for disease development are en-
vironmental, including cigarette smoke, and there is also a 
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genetic component with recent heritability estimates ranging 
from 50% to 66%.3 However, the mechanisms underlying ge-
netic effects are mostly unclear.
Lung function measurements are essential parameters 
used in the diagnosis of COPD and are, therefore, ideal quan-
titative traits to use in studies aiming to identify the genetic 
risk factors for COPD. The most commonly used are forced 
expired volume in 1 second (FEV1), forced vital capacity 
(FVC), and FEV1/FVC ratio. Using lung function phenotypes 
for genetic studies allows for additional subjects and, there-
fore, increased power to detect causal variants with the as-
sumption that the genetics of lung function and COPD share 
some commonality. The most recent and largest genome wide 
association study (GWAS) for lung function identified 279 
loci showing association with FEV1, FVC, or FEV1/FVC.
4 
Moreover, GWAS in COPD subjects have identified that 
there is significant overlap between signals associated with 
COPD risk and signals associated with lung function mea-
surements.5 There is now a need to translate GWAS signals 
to biological understanding by studying the underlying func-
tional effects of the genetic variants in respiratory health and 
disease.
The 6q24 locus is one that has reproducibly been asso-
ciated with lung function measurements5- 7 with the most 
recent GWAS identifying two signals from this locus. 
First, rs17280293 (A > G) (signal 1) is a missense variant 
(Ser123Gly) within the coding region of GPR126 which 
is associated with reduced FEV1/FVC (risk allele A, al-
lele frequency = 97.3%, beta = −0.1803, and P = 2.34E- 
131).4 This signal is also associated with an increase in FVC 
(P = 8.58E- 22).4
The second signal (signal 2) comes from an intronic 
SNP within the GPR126 coding region (rs7753012 (T/G), 
risk allele T for reduced lung function (FEV1/FVC), allele 
frequency = 69.5%, beta = −0.0712, and P = 4.71E- 165).4 
This second signal also showed association for reduced FEV1 
(P = 7.09E- 23).
Moreover, missense variant Ser123Gly (signal 1) is also 
associated with diffusing capacity of the lung (DLCO/VA) 
(risk allele A, beta = −0.07, and P value = 1.51E– 10) even 
after adjustment for FEV1/FVC.
8 This study also noted that 
GPR126 expression was decreased in lung tissue obtained 
from more severe COPD patients compared with never smok-
ers and in patients with lowered DLCO/VA compared to nor-
mal DLCO/VA controls.
8
GPR126 belongs to the adhesion GPCRs (aGPCRs) sub- 
family of GPCRs. This family has 33 members, defined by 
the presence of their large N- terminal regions, which can 
be as large as 6000 amino acids long, in addition to the 
canonical 7 transmembrane spanning regions (7TM).9,10 
These extracellular regions contain several conserved do-
mains that are important for adhesion interactions. All aG-
PCRs contain the GPCR autoproteolysis- inducing (GAIN) 
domain which contains the GPCR proteolysis site (GPS) 
motif.11,12 During biosynthesis, aGPCRs are autoproteol-
ysed at this site which results in a cleaved receptor that 
nonetheless remains associated at the cell surface.13,14 
While the extracellular domain (ECD) is still associated 
with the 7TM it exerts an inhibitory effect on receptor sig-
naling and it is hypothesized that interaction with a poten-
tial ligand or mechanical stimuli would result in removal 
or rearrangement of the ECD thereby removing the inhibi-
tory effect.15,16 This reorganisation releases a short peptide 
sequence which lies C- terminal to the GPS cleavage site 
(termed stachel). This stachel peptide acts as a tethered ag-
onist and can activate receptor signaling.17 These receptors 
can signal via traditional GPCR pathways via G proteins 
and18 to date Gα12/13, Gαo, Gαs, Gαi, and Gαq have all 
been shown to be involved in aGPCR signaling pathways.15
GPR126 is one of the more well- studied aGPCRs with 
known roles in peripheral nerve development, angiogene-
sis, and inner ear formation via canonical GPCR signaling 
through Gas- and Gai- mediated regulation of intracellular 
cAMP.19- 25 Complete knockout of GPR126 in mice leads 
to embryonic lethality due to cardiovascular failure.26 
However, incomplete knockout where the ECD is still pres-
ent leads to mice which have limb defects, highlighting an 
independent signaling role for the ECD once dissociated 
from the 7TM.23,26,27 A number of potential ligands have 
been identified for GPR126 including laminin- 211 and col-
lagen type IV, which are predicted to involve binding to the 
complement C1r/C1s, Uegf, Bmp1 (CUB), and pentraxin 
(PTX) domains in the ECD.23,28 Ser123Gly (signal 1) lies 
within the CUB domain and, therefore, could have poten-
tial effects on ligand binding. Moreover, recent studies have 
identified additional mechanisms which modulate GPR126 
activity, including the importance of a calcium- binding do-
main in the ECD, mutations in which lead to defects in 
myelination and ear development in vivo.29 Furthermore, 
alternative splicing of exon 6 (present in 2/4 known iso-
forms) modulates GPR126 signaling activity.29 Isoforms 
lacking exon 6 maintain a closed conformation and show 
decreased signaling activity compared to those with exon 
6, which inhibits the closed conformation.29
Polymorphisms in GPR126 have been associated with 
scoliosis in humans.18,30- 33 One such variant, rs41289839, 
has been shown to decrease the expression of exon 6, which 
would be expected to dampen GPR126 signaling activity.18,29
Despite advances in understanding of GPR126 func-
tion, the role of GPR126 in the human lung is currently 
unknown and, therefore, the mechanisms by which genetic 
variants at the GPR126 locus are associated with lung func-
tion are not understood. However, it is known that GPR126 
is differentially expressed throughout human lung develop-
ment, suggesting that it may be important for normal lung 
development.34
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We hypothesized that GPR126 is the causal gene under-
lying the genetic associations at this locus and that either al-
teration in protein structure or regulation of the levels of the 
mRNA/protein underlie this effect. In this study, we aimed to 
identify potential causal variants within GPR126 and identify 
potential mechanisms by which altered GPR126 expression/
function may affect airway biology.
2 |  MATERIALS AND METHODS
2.1 | RNA isolation
RNA isolation was carried out using the GenElute™ 
Mammalian Total RNA Miniprep Kit as per the manufac-
turer’s instruction (Sigma).
2.2 | cDNA synthesis
cDNA synthesis was performed using the Superscript First 
Strand Synthesis System for RT- PCT kit (Invitrogen).
2.3 | Primary bronchial epithelial 
cell culture
Human Bronchial Epithelial Cells (HBECs) were pur-
chased from Lonza (Wokingham, UK) (Supplementary 
Table 1). HBECs were maintained in PneumaCult- Ex Basal 
Medium (490 ml PneumaCult- Ex Basal Medium plus 10 ml 
PneumaCult- Ex 50X Supplement and 500 µl 200X hydrocor-
tisone stock solution) with the addition of 5 ml of antibiotic, 
antimycotic solution containing penicillin, streptomycin, and 
fungizone (PSF).35
2.4 | Human airway smooth muscle 
cell culture
Human lung tissue was obtained from the Nottingham Health 
Science Biobank or the Papworth Hospital Tissue Bank from 
patients undergoing lung resection surgery. Human airway 
smooth muscle (HASM) cells were obtained from lung tissue 
using the explant model outlined below. Details of these tis-
sue donors can be found in the supplement (Supplementary 
Table 2). Written consent was obtained from all patients 
and the study was conducted under the approval of the re-
search Tissue Banks (ethics reference 10/H1008/72 and 08/
H0304/56+5).
Small sections of airways were dissected from the sur-
rounding tissue and the resulting explants were smeared 
across the bottom of one well of a 6- well plate. Cells were 
grown out from explants cultured in DMEM supplemented 
with 10% of FCS and 5% of PSF.
2.5 | HEK293 cell culture
GloResponseTM CRE- luc2P HEK293 cells (Promega, 
E8500) were grown in Dulbecco’s Modified Eagles Medium 
with 4500 mg/L glucose, L- glutamine, and sodium bicarbo-
nate, without sodium pyruvate (DMEM) with the addition of 
10% FCS with 50 µg/ml hygromycin B.
2.6 | Recombinant cell line production
GloResponse™ CRE- luc2P HEK293 cells were transfected 
using Fugene® 6 (Promega) with a lentivirus plasmid con-
taining full length GPR126 and the puromycin resistance 
gene at a 1.5:1 Fugene: DNA ratio using the protocol was 
provided by the manufacturer. Cells expressing GPR126 
were selected by puromycin treatment. Plasmids were de-
signed and purchased from VectorBuilder (Chicago, USA).
2.7 | Luciferase assays
Transfected cells were seeded into 96- well plate 24 hours 
prior to stimulation and treated with the stachel peptide (1 
mM) or other agonists for 4 hours. Bright- Glo buffer and 
Bright- Glo substrate (Promega) were mixed and 100 µl of 
the solution was added to each well of a 96- well plate to ter-
minate the assay. Plates were incubated at room temperature 
for at least 2 minutes before luminescence was measured on 
a Flexstation 3 microplate reader (Molecular Devices) for 0.5 
seconds/well.
2.8 | cAMP assays
cAMP responses were measured as previously described.36 
In brief, HBEC and HASM cultures were seeded into 24- well 
plate 24 hours prior to treatments. Cell cultures were loaded 
with 3H adenine for 2 hours. Cells were washed with serum- 
free media prior to stimulation. Experiments were stopped 
and cells were lysed by adding concentrated HCl. 14C- cAMP 
was added to each well to allow for normalization across the 
columns. The contents of each well were then transferred to 
Dowex columns and three milliliters of H2O was added to 
wash each column. Dowex columns were placed on top of 
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alumina columns. Six milliliters of H2O was added to dowex 
columns and allowed to drip through both sets of columns. 
Dowex columns were removed and the alumina columns 
were placed over scintillation vials. Five milliliters of 0.1 
M of imidazole was applied and allowed to drip through the 
columns into the scintillation vials. Ten milliliters of scintil-
lation fluid was added to each vial and vials were counted 
on a Packard Scintillation counter using a 3H/14C dual- count 
program for 5 minutes per vial. cAMP accumulation was 
calculated by normalizing 3H counts per well to 14C counts. 
Each condition was performed in three replicate wells.
2.9 | Library preparation for RNA- 
sequencing
Library preparation and RNA- sequencing were carried out 
by Oxford Genomics Centre. RNA was quantified using 
RiboGreen (Invitrogen, Glasgow, UK) on the FLUOstar 
OPTIMA plate reader (BMG Labtech, Aylesbury, UK) 
and the size profile and integrity analyzed on the 4200 
TapeStation (Agilent). RNA was normalized to 100 ng prior 
to library preparation. Polyadenylated transcript enrichment 
and strand- specific library preparation were completed using 
NEBNext Ultra II mRNA kit (NEB, Hitchin, UK) follow-
ing the manufacturer’s instructions. Libraries were amplified 
on a Tetrad (Bio- Rad, London, UK) using in- house unique 
dual- indexing primers. Individual libraries were normalized 
using Qubit, and the size profile was analyzed on the 4200 
TapeStation. Individual libraries were normalized and pooled 
together accordingly. The pooled library was diluted to ~10 
nM for storage. The 10 nM library was denatured and further 
diluted prior to loading on the sequencer.
2.10 | RNA- sequencing
Paired end (75 bp) sequencing was performed using a 
HiSeq4000 platform and HiSeq 3000/4000 PE Cluster Kit 
and 150 cycle SBS Kit (Illumina, Cambridge, UK), generat-
ing a raw read count of ~30 million reads per sample.
2.11 | Analysis of RNA- sequencing data
Processing of the RNA- sequencing data was performed using 
a Unix operating system. Adaptor sequence and quality trim-
ming were performed using Scythe (https://github.com/vsbuf 
falo/scythe) and Sickle (https://github.com/najos hi/sickle), 
respectively. Alignment of RNA- Seq reads to genome build 
GRCh37 was carried out using Tophat package.37 Analysis 
of trimmed RNA- sequencing files was performed using the 
Cufflinks package37 as we have done previously.38 Cuffdiff 
and Cuffnorm were used to determine differential (5% FDR) 
and gene expression was normalized to library size, respec-
tively. Gene set enrichment analysis was performed using the 
GSEA software from the Broad Institute and the Molecular 
Signatures Database (MSigDB).39,40 Volcano plots and heat-
maps were produced in RStudio using ggplot241 and pheat-
map,42 respectively.
3 |  RESULTS
3.1 | Variants on chromosome 6 associated 
with lung function alter GPR126 amino acid 
sequence and affect GPR126 expression levels
To identify causal variants underlying the two association 
signals with FEV1/FVC ratio, we sought to identify SNPs 
which could be potentially causative. This included identify-
ing SNPs which have regulatory effects such as expression 
quantitative trait loci (eQTLs) and non- synonymous variants 
using GTEx Portal V8 Release (https://www.gtexp ortal.org/
home/)43 and Open Target Genetics (https://genet ics.opent ar-
gets.org/). We also used LDlink and HaploReg V4.1 to iden-
tify additional variants that were in linkage disequilibrium 
(LD) with the two sentinel variants (r2 > 0.1).
Signal 1 (rs17280293) results in missense variant 
Ser123Gly. Using LDlink, we identified 64 SNPs in LD with 
signal 1 (r2  >  0.1) including missense variant rs11155242 
((Lys230Gln), r2 = 0.1442, D’ = 1). Neither SNP is an eQTL 
for GPR126 expression in lung tissue in the GTEx database 
(V8 release). However rs17280293 is an eQTL for GPR126 
expression in blood (eQTLGen database)44 with the G al-
lele (higher lung function) associated with reduced GPR126 
expression (beta: −0.205, pval:7.1e- 16). In addition, 
rs11155242 (C, correlated with rs17280293 G) is an eQTL 
for GPR126 in a number of tissues including blood, macro-
phage, monocytes, and T- Cells.45 SIFT46 and PolyPhen- 247 
were used to assess potential pathogenicity of these two cod-
ing region variants. Both tools predicted rs17280293 to be 
damaging to protein function potentially via the insertion of 
a smaller amino acid and loss of structure and rs11155242 to 
be benign/tolerated.
Signal 2 had 262 SNPs in LD (r2 > 0.1) and is in linkage 
equilibrium with rs17280293 (r2: 0.0836) suggesting inde-
pendence from signal 1. Within this LD block there are two 
SNPs associated with scoliosis rs41289839 (r2 = 0.1746) and 
rs6570507 (r2 = 0.9006) with rs7753012. The signal 2 senti-
nel SNP (rs7753012) is an eQTL for GPR126 expression in 
the esophagus with the G allele (higher lung function) asso-
ciated with lower expression of GPR126 (NES: - 0.15, pval: 
0.000031). Moreover, the two scoliosis SNPs are also eQTLs 
for GPR126 in other tissues including blood, cultured fibro-
blasts, and skeletal muscle.43
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3.2 | GPR126 is expressed in human lung 
tissue and structural airway cells
To determine the expression profile of GPR126 in human 
structural airway cells, we performed RNA- sequencing on 
RNA extracted from HASM cells and HBECs. HBECs were 
from healthy donors purchased from Lonza (Wokingham, 
UK) and HASM cells were grown from lung tissue donors. 
Normalized expression values are shown as the number of 
fragments per kilobase of transcript per million mapped reads 
(FPKM). GPR126 is expressed in both cell types, with higher 
expression levels observed in HBEC (n  =  9 donors, mean 
= 17.5 FPKM, min = 6.3, and max = 27.1) compared with 
HASM (n = 5 donors, mean = 5.7 FPKM, min = 0.3, and 
max = 19.2) (Figure 1A).
In order to assess if GPR126 expression in human lung 
tissue varies in disease states such as COPD, we utilized 
RNA- seq datasets available on the Gene Expression Omnibus 
(GEO). We searched the database with the following search 
terms; Lung tissue, airway smooth muscle, bronchial epithe-
lial, COPD, and RNA- seq. We identified two datasets which 
allow comparison of gene expression in lung tissue/cell types 
between COPD and control.
GSE57148 contains a dataset comparing lung tissue from 
patients with normal spirometry vs tissue from COPD pa-
tients.48 GPR126 expression is expressed in human lung tis-
sue and at significantly higher levels in COPD patients vs 
controls (COPD FPKM median 10.5, control FPKM median 
9.1, and P = .0164) (Figure 1B). GSE12 4180 contains RNA- 
seq data from large airway epithelium, alveolar macrophage, 
and peripheral blood samples from COPD cases and con-
trols.49 Differential expression of GPR126 was not observed 
in large airway epithelium, alveolar macrophages, or periph-
eral blood between controls and COPD patients, although 
sample numbers were low (Figure 1C- E).
3.3 | Adhesion GPCR expression in 
structural airway cells
To contextualize the expression levels of GPR126, we an-
alyzed RNA- seq data in HASM and HBECs for the wider 
F I G U R E  1  Average FPKM values for all donors is shown for HBECs (n = 9) and HASMs (n = 5) (A). RNA- seq data from whole lung 
tissue was downloaded from GEO (GSE57148) and GPR126 expression was compared in RNA extracted from healthy lung tissue and lung tissue 
from COPD patients (B). FPKM values from control (mean = 9.1, min = 2.1, and max=18.4) and COPD patients (mean = 10.1, min = 1.7, and 
max=22.5) were compared using an unpaired t test. Data were normally distributed as determined by a Shapiro- Wilk normality test. GPR126 
expression in COPD vs controls was compared in GSE12 4180 in different cell types (C- E). No significant differences in expression between COPD 
and control were observed
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family of aGPCRs as well as the expression levels of a well- 
studied airway GPCR for comparison, the β- 2 adrenergic re-
ceptor (ADRB2) (Table 1). Seventeen of the 33 aGPCRs are 
expressed in at least one cell type and GPR126 is expressed 
in both HASM and HBEC at higher levels than ADRB2.
3.4 | GPR126 signals via cAMP- mediated 
pathways in structural airway cells
In order to assess GPR126 signaling activity and effects 
of the Ser123Gly variant to potential ligands, we produced 
a recombinant cell system using the GloResponse™ CRE- 
luc2P HEK293 Cell Line (Promega) to overexpress human 
GPR126. We created cells lines expressing the Ser123 and 
Gly123 variants of the receptor. Cells were treated with col-
lagen type IV (3 µg/ml) and laminin- 211 (200 ng/µl) for 4 
hours; however neither agonist induced signaling.23,28 Cells 
were then treated with the activating peptide stachel (1 mM) 
for 5 hours17 and we observed a dose- dependent increase 
in luciferase activity in cells expressing both variants but 
no increase in signal in empty vector or no vector controls 
(Figure  2A). However, we did not identify any genotype- 
specific effects. We also measured cAMP accumulation in 
these same cells using column chromatography, showing in-
creased levels of cAMP after 1 mM stachel treatment at 1 and 
4 hours (Figure 2B).
We then tested whether stachel could activate GPR126 
signaling in primary cultured human airway structural cells. 
HASM cells and HBECs were treated with stachel peptide 
(1 mM) for 1 hour with pre- incubation with IBMX (10 uM). 
Accumulation of cAMP was measured using column chro-
matography. In HASM cells we observed a mean fold in-
crease in cAMP of 21.5 ± 3.4 (P = .0079) and in HBECs a 
more modest but still significant response (2.1 ± 0.5 mean 
fold increase (P = .0278)) (Figure 2C- D).
3.5 | GPR126 expression increases as cells 
become more confluent and after stachel 
stimulation
These data show that activation of cAMP- driven gene ex-
pression occurs after stimulation of GPR126 expressing cells 
with stachel peptide. Therefore, to gain insight into poten-
tial biological functions driven by changes in gene expres-
sion in HASM and identify downstream targets of GPR126 
activation, we treated HASM cells with stachel (1 mM) for 
4 and 24 hours and performed RNA- sequencing. Cuffnorm 
was used to generate normalized expression values (FPKM) 
for individual genes and isoforms in HASM cells (n = 4 in-
dependent experiments, one donor). GPR126 is expressed at 
higher levels 24 hours after treatment and is significantly el-
evated after stachel treatment for 24 hours compared to basal 
and scrambled (P = .0071) (Figure 3). There was no signifi-
cant difference in GPR126 expression between the different 
conditions after 4 hours.
3.6 | GPR126 activation results in 
differential regulation of >300 genes
To assess the downstream genes and pathways and, there-
fore, potential biological implications of GPR126 activation, 
we used Cuffdiff to assess differentially regulated genes be-
tween HASM cells treated with stachel and those treated with 
a scrambled control peptide. GPR126 activation by stachel 
peptide in HASM cells resulted in 345 (135 upregulated 
and 210 downregulated) and 356 (109 upregulated and 247 
downregulated) differentially expressed genes at 4 (Figure 4) 
and 24 hours (Figure 5), respectively, vs a scrambled con-
trol peptide. These data are based on 1% FDR and we only 
considered genes which had a baseline expression of FPKM 
>1. At 4 hours, top genes (defined by q value then fold 
change) included FAM150A, KRTAP2- 3, ARID5A, ATP8B1, 
T A B L E  1  Median and range expression (in FPKM) of the 





Average FPKM in 
HASM cells (n = 5)
ADGRA2 (GPR124) 0.1 (0- 1.6) 24.3 (15.2- 38.9)
ADGRA3 (GPR125) 18.6 (13.6- 29) 11.4 (9.1- 13.2)
ADGRB2 (BAI2) 1.2 (0.4- 2.4) 5.9 (2.9- 12.2)
ADGRC1 (CELSR1) 45.5 (31.3- 55.9) 0.9 (0.2- 1.8)
ADGRC2 (CELSR2) 17.6 (9.4- 37.2) 1 (0.23- 2.2)
ADGRC3 (CELSR3) 19 (0.6- 25.5) 0.8 (0.3- 1.2)
ADGRD1 (GPR133) 0 (0.008- 0.012) 9.6 (0.2- 34.4)
ADGRE5 (CD97) 10 (1.5- 13.3) 24 (6- 32.2)
ADGRF1 (GPR110) 10.6 (2.6- 29.9) 0 (0- 0)
ADGRF2 (GPR111) 17.9 (13- 24.9) 0.1 (0- 0.3)
ADGRF4 (GPR115) 17.9 (13- 24.9) 0.1 (0- 0.3)
ADGRG1 (GPR56) 107.3 (67.7- 149.2) 3.2 (0.3- 6.2)
ADGRG2 (GPR64) 0.1 (0.04- 0.35) 0.4 (0.2- 0.6)
ADGRG6 (GPR126) 17.5 (6.3- 27.1) 5.7 (0.2- 19.2)
ADGRL1 (LPHN1, 
CIRL- 1, and CL1)
1.9 (0.7- 2.8) 2 (1.3- 2.3)
ADGRL2 (LPHN2, 
CIRL- 2, and CL2)
15.3 (10.2- 26) 14.4 (8.5- 22.9)
ADGRL4 (ELTD1 
and ETL)
0.2 (0- 0.7) 6 (3.8- 11)
ADRB2 14.9 (8.5- 32.8) 4 (0.1- 8.5)
Note: Only aGPCRs with FPKM >1 in either HASM cells or HBECs are 
included in the table except GPR64.
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ANKRD1, HDAC9, KRTAP1- 5, CTGF, NLRP10, and 
KLHL38 (all downregulated) and SYT12, ZBTB7C, HEATR6, 
IFI27, SLC16A9, TMEM100, ZNF813, ADAM8, PDE3A, 
and RASD2 (all upregulated). At 24 hours top downregulated 
genes were RP11- 87N24.3, snoU13, SERPINE1, TM4SF20, 
OXTR, LAD1, TNNT2, ANO1, MAP3K7CL, and ACTG2 and 
upregulated genes were ZBTB7C, TMEM100, CACNA1G, 
PTPRN, LRRN3, PLP1, HTRA3, YPEL4, RNF112, and 
SLITRK6. The full list of differentially expressed genes can 
be found in Supplementary Table 3 (4 hours) and Table 4 (24 
hours).
3.7 | Genes implicated in airway diseases are 
regulated by GPR126 activation
After identifying genes which were differentially regu-
lated at the two time points, we compared the genes dif-
ferentially expressed at 4 hours to those at 24 hours. We 
found that ~20% of genes were differentially regulated by 
GPR126 activation with the same direction of effect with 
40 upregulated and 74 downregulated (Figure 6A). To 
focus our analysis, we then looked at the genes which were 
differentially expressed using an arbitrary cut off of a ≥2 
fold change in either direction at both time points (Figure 
6B). There were 26 genes that met this criteria, these in-
clude genes with previously reported roles in airway dis-
ease such as IL33 (upregulated), CTGF (downregulated), 
and SERPINE1 (downregulated).50- 52
3.8 | Pathway analyses suggests GPR126 
may have a role in cell proliferation
Gene Set Enrichment Analysis (GSEA) was used from the 
Broad Institute to identify gene sets/biological pathways ef-
fected by GPR126 activation.40 There were nine gene sets 
that were enriched (1% FDR) by GPR126 activation in the 
hallmark gene sets. No gene sets were enriched at 4 hours 
using the hallmark gene set. The differentially regulated gene 
sets at 24 hours are involved in cell cycle regulation and cell 
proliferation (Table 2). These processes are known to be 
F I G U R E  2  Luciferase response of HEK293 cells transfected with GPR126 to increasing concentrations (100- 1000µM) of the stachel peptide 
after 5 hours of incubation (n = 5) (A). cAMP measurements in GPR126Ser123 and GPR126Gly123 HEK293 cells in response to stachel peptide, 
isoprenaline, and forskolin treatment for 10, 60, 120, and 240 minutes with pre- treatment with IBMX (B). cAMP accumulation in HASM cells (C) 
and HBECs (D) pre- treated with IBMX and then, treated with Stachel (1 mM) or isoprenaline (10 µM) for 1 hour (n = 5). Data shown are mean ± 
SEM. SFM, serum free media
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regulated by aGPCRs in other cell types. We also analyzed the 
list of differentiated genes (1% FDR) through The Database 
for  Annotation,  Visualization, and  Integrated  Discovery 
(DAVID).53 The most significant results grouped differen-
tially expressed genes into Mitosis (P = 2.23E- 06), cell divi-
sion (P = 1.54E- 03), and cell cycle (P = 9.11E- 03).
4 |  DISCUSSION
In this study, we hypothesized that genetic variants that af-
fect GPR126 expression or function may contribute to pro-
cesses that lead to airway disease. We aimed to identify 
potential causal variants driving the GWAS association sig-
nals observed for FEV1/FVC and explore the potential role 
of GPR126 in human airway structural cells. Signal 1 has a 
coding region sentinel SNP resulting in Ser123Gly, a variant 
predicted to be damaging to protein function, but in recom-
binant cell experiments we were unable to detect any altered 
signaling as a consequence of this polymorphism. The signal 
2 top variant however is an eQTL in a range of tissue types 
where it has been studied, suggesting that altered GPR126 
expression could be driving at least some of the genetic asso-
ciations seen. We identified GPR126 expression in the lung 
and in HASMs and HBECs and identified that GPR126 could 
have a role in airway remodeling via transcriptomic analysis.
From the analysis of the LD structure around the senti-
nel SNPs, the most compelling SNP for further analysis was 
the Ser123Gly variant (signal 1), predicted to be damaging 
to protein function. Based on the genetics from the Shrine 
et al, 2019 GWAS, the Ser123 allele (common) is protective 
against lung function decline.
However, we were unable to detect a functional effect of 
the Ser123Gly variant in recombinant cell models. There are 
several potential explanations for this. First, stachel binds C- 
terminal to the Ser123Gly position and, therefore, any po-
tential effects of this amino acid change on ligand binding 
may be bypassed. We were unable to test any differential ef-
fects of the reported ligands collagen type IV and laminin 
211 as these did not activate receptor signaling in our system. 
We cannot exclude that the recombinant expression system 
(higher than endogenous) altered the state of GPR126 and 
responsiveness to ligand. Second, we overexpressed the alpha 
2 variant of the receptor, which lacks exon 6 of the full- length 
protein and this may, therefore, be a limitation. It has recently 
been shown that transcripts lacking exon 6 exist in a closed 
conformation and signal less readily than GPR126 transcripts 
with exon 6 present.18 These factors may explain why signal-
ing activity was not observed when cells were treated with 
collagen type IV or laminin 211. However, we saw robust 
effects on signaling in both cell lines and also in primary 
cultured HASM cells following activation with the stachel 
peptide suggesting any genotype- specific effects should have 
been found with the transcript we expressed.
Our eQTL analyses suggest that alleles associated with 
higher lung function are associated with reduced GPR126 
mRNA expression levels. Similarly, we identified elevated 
GPR126 mRNA levels in lung tissue from COPD patients 
vs normal spirometry controls. Therefore, we hypothesis that 
increased expression/activity of GPR126 may be damaging 
in the lung. We chose to study this in airway smooth mus-
cle, given that eQTL signals were observed in fibroblast and 
smooth muscle containing tissues.
Given the potential for altered gene expression to be driv-
ing effects of GPR126 signaling, we therefore, used RNA- 
seq to identify the potential roles of GPR126 in HASMs by 
activating the receptor with the activating peptide stachel. 
GPR126 activation by stachel peptide resulted in 345 and 
356 differentially expressed genes at 4 and 24 hours, respec-
tively. There were distinct transcriptome profiles at the two 
time points with a ~20% overlap of common differentially 
regulated genes. Therefore, while the two time points may 
identify early and late response genes, there is increased con-
fidence that the genes differentially regulated at both time 
points are driven by real effects of GPR126 activation. The 
genes differentially regulated following the activation of 
GPR126 are predominantly in pathways controlling mitosis 
and cell division.
F I G U R E  3  GPR126 mRNA expression increases over time in 
cultured HASM which is augmented by stachel peptide stimulation of 
cells. GPR126 mRNA expression in basal HASM cells, cells treated 
with stachel (1 mM) or scrambled- treated cells at 4 and 24 hours. 
FPKM values for each condition were compared between the two time 
points using a two- way ANOVA with Sidak’s multiple comparisons 
test. In addition, FPKM values were compared within each time point 
for each condition using a two- way ANOVA with Tukey’s multiple 
comparisons test. Data shown are mean ± SEM from four experiments
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We also found that GPR126 mRNA expression in HASMs 
generally increases over time in culture. One potential expla-
nation for the increase in GPR126 expression at 24 hours 
may be that the cells were more confluent and, therefore, 
there are more cell- cell and cell- matrix interactions. As the 
cells proliferate, more matrix is deposited and an increase 
in matrix would be expected to include matrix ligands for 
GPR126. aGPCRs are known to modulate a number of cel-
lular functions including cell migration, adhesion, polarity, 
and guidance via these adhesion interactions.54 Moreover, it 
F I G U R E  4  Volcano plot shows differentially expressed (1% FDR, FKPM >1) genes after stachel treatment vs scrambled control after 4 
hours. Genes which are labeled are the top 10 genes ranked first by q value then by fold change. Colored dots represent genes which reach 1% FDR. 
Heatmaps show gene expression across individual replicate experiments. Genes shown are the top 50 ranked first by q value then by fold change. 
Genes which were not differentially regulated in three out of four replicates were removed. Brown represents upregulation and green represents 
downregulation
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is also known that GPR126 is vital for normal tissue develop-
ment via interactions with the ECM.23,28 Therefore, GPR126 
may be upregulated to facilitate these functions when there 
is increased cell- cell and cell- matrix contact. GPR126 activ-
ity also increased after stachel treatment providing evidence 
for a positive feedback loop. This may also explain increased 
GPR126 expression in lung tissue from COPD patients. We 
did not directly test the relationship between GPR126 expres-
sion and cAMP signaling.
Differentially regulated genes after stachel activation in-
clude IL33, CTGF, and SERPINE1, all of which have known 
roles in airway disease and present possible mechanisms for 
F I G U R E  5  Volcano plot shows differentially expressed (1% FDR, FKPM >1) genes after stachel treatment vs scrambled control after 24 
hours. Genes which are labeled are the top 10 genes ranked first by q value then by fold change. Colored dots represent genes which reach 1% FDR. 
Heatmaps show gene expression across individual replicate experiments. Genes shown are the top 50 ranked first by q value then by fold change. 
Genes which were not differentially regulated in three out of four replicates were removed. Brown represents upregulation and green represents 
downregulation
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GPR126 involvement in airway disease. Chronic inflamma-
tion of the airways is a key feature of many diseases causing 
airflow obstruction and airway smooth muscle secretes a va-
riety of chemokines and cytokines that can perpetuate airway 
inflammation.55 For example, IL33 (upregulated by GPR126 
activation) is a well characterized cytokine that plays an 
important role in several chronic inflammatory diseases by 
promoting inflammatory cytokine production.56 Serum lev-
els of IL- 33 and its receptor ST2 are elevated in patients 
with COPD compared to control subjects and peripheral 
blood lymphocytes from COPD patients release more IL33 
in response to stimulus than healthy controls.52 As GPR126 
activation upregulated IL33 expression, reduced GPR126 ex-
pression in individuals carrying the protective alleles could 
potentially result in less IL33 being produced although this 
requires further investigation.
Airway remodeling results from a wide range of mecha-
nisms involving smooth muscle cell hyperplasia, increased 
activation of fibroblasts and myofibroblasts, increased depo-
sition of the ECM, and aberrant inflammatory responses. 
Airway smooth muscle undergoes alterations in health and 
disease characterized by cell proliferation, hypertrophy, and 
migration, and the expression of chemokines and cytokines is 
important in regulating airway inflammation.55 Furthermore, 
smooth muscle mass is altered in COPD due to hypertrophy 
and hyperplasia.55 We observed increased GPR126 expres-
sion in more confluent smooth muscle cells and, therefore, 
perhaps increased smooth muscle mass or ECM deposition 
in COPD is responsible for increased GPR126 expression ob-
served in lung tissue from COPD patients.
CTGF is a gene downregulated by GPR126 activation 
which has roles in inflammation and tissue remodeling. 
This ECM protein recruits fibroblasts to wound sites, along 
with other inflammatory mediators such as TGF- β and 
IL- 8/CXCL8. CTGF has a known role in pulmonary fibro-
sis and airway remodeling and has been shown to modulate 
a number of signaling pathways involved in cell adhesion 
and migration, angiogenesis, myofibroblast activation, and 
extracellular matrix deposition, which together can result in 
tissue remodeling and fibrosis.51 These processes are also 
in keeping with what is known about adhesion GPCR biol-
ogy.10 Elevated CTGF expression contributes to expression 
of ECM proteins, cell migration, and the myofibroblastic 
phenotype in tissue repair.57 In mouse lung tissue, CTGF 
expression and promoter activity are elevated after bleo-
mycin challenge.58 CTGF exerts profibrotic effects and 
F I G U R E  6  Differentially expressed genes at both time points (A). Fold change in FPKM at both time points. Genes shown are those which 
are differentially expressed at both time points with a fold change ≥ 2 and GPR126 (B)
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contributes to lung fibrosis via transcriptional regulation of 
COL1A2.58 Altered CTGF expression might seem unlikely 
to mediate the effects of GPR126 variants as expression 
was downregulated following GPR126 activation, although 
increased remodeling would be expected to lead to a re-
duced FVC and hence downregulation of CTGF could be 
working through this route.
SERPINE1 (PAI- 1) (also downregulated by GPR126 ac-
tivation) has been shown to be upregulated in emphysema 
lung and increased expression of PAI- 1 suppresses fibri-
nolysis leading to pathological fibrin deposition and tissue 
damage.50,59 Moreover, PAI- 1 knockout mice display an 
emphysema- like phenotype, possibly due to an imbalance in 
protease- antiproteases activity in the lung– – a known factor 
in emphysema development.60 Elevated levels of PAI- 1 are 
observed in the sputum of COPD patients and these levels 
were more elevated in more severe COPD cases.61,62 PAI- 1 
plays a critical role in fibrosis development in a number of 
tissues including in the lung63 and is produced by smooth 
muscle cells.59 As with CTGF, the direction of effect fol-
lowing GPR126 activation initially seems inconsistent with 
altered SERPINE1 levels mediating effects of GPR126 ac-
tivation but again this could be working through increased 
FVC rather than altered FEV1.
In addition to potential roles in inflammation and remod-
eling, GPR126 activation resulted in the differential regula-
tion of genes within pathways involved in proliferation and 
cell cycle regulation. It has also been recently shown that 
GPR126 knockdown results in an increased proliferation of 
pulmonary artery smooth muscle cells where increased ex-
pression of GPR126 was associated with decreased prolifer-
ation.64 These results are consistent with our suggestion that 
GPR126 plays a role in control of cell proliferation in the 
lungs.
There are limitations to our study. First, we were unable 
to detect GPR126 protein expression due to technical chal-
lenges and, therefore, we were unable to confirm cell sur-
face expression of GPR126 in our recombinant cell system 
and in the primary cells. Moreover, as we were unable to 
detect signaling using identified GPR126 ligands we chose 
to use the GPR126 stachel peptide, which has been shown 
to cross- activate other receptors within and across aGPCR 
families. For example, peptides derived from GPR64 and 
GPR126 do cross- activate their respective receptors.65 
However, the peptide from GPR126 shows higher potency 
and efficacy on its originating receptor. To address this, 
we assessed GPR64 expression levels in HASM cells and 
HBECs prior to experimentation. Expression of GPR64 
was at the lowest level of detection with FPKM <1 (Table 
1). These data provided some confidence the signal was 
GPR126 derived, however we cannot completely exclude 
the possibility that GPR64 may make a minor contribution 
to signaling.
Collectively, these differentially expressed genes and 
pathways highlight a potential novel role for GPR126 in reg-
ulating the connected processes of airway remodeling and 
airway inflammation– – both key processes in the pathophys-
iology of COPD. The genetic analyses suggest that GPR126 
increased expression/activity may be damaging and we hy-
pothesize that this could result in dysregulation of pathways 
involved in smooth muscle cell proliferation which may, 
therefore, contribute to airway disease.
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T A B L E  2  Nine gene sets are downregulated by GPR126 activation in the hallmark gene sets





Hallmark E2F targets 199 −0.71 −2.04 0 tags = 66%, list = 14%, and signal = 76% 24 hours
Hallmark MYC targets 199 −0.7 −1.97 0 tags = 67%, list = 19%, and signal = 83% 24 hours
Hallmark G2M checkpoint 199 −0.68 −1.93 0 tags = 60%, list = 12%, and signal = 68% 24 hours
Hallmark MTORC1 signaling 199 −0.62 −1.74 0.001 tags = 63%, list = 18%, and signal = 76% 24 hours
Hallmark MYC targets v2 58 −0.68 −1.65 0.0033 tags = 62%, list = 18%, and signal=75% 24 hours
Note: Size = number of genes in the gene set after filtering out those not in the expression dataset. ES = enrichment score for the gene set. This is the degree to which 
the gene set is overrepresented at the top or bottom of the ranked list of genes in the expression dataset. NES = normalized enrichment score. q value = false discovery 
rate– – the estimated probability that the NES represents a false positive. Leading edge subset = subset of members that contribute the most to the ES. Tags = the 
percentage of genes contributing to the ES. List = percentage of genes in the ranked gene list before the peak in the running ES. This gives an indication of where in 
the list the ES is attained. Signal = the ES strength that combines the two previous statistics.
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